

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/540,343	10/06/1995	DENNIS E. HALLAHAN	ARCD:194	8900
75	90 04/21/2004		EXAMINER	
Fulbright & Jaworski L.L.P. 600 Congress Avenue Suite 2400			PRIEBE, SCOTT DAVID	
Austin, TX 78701			ART UNIT	PAPER NUMBER
			1632	
			DATE MAILED: 04/21/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		08/540,343	HALLAHAN ET AL.			
		Examiner	Art Unit			
		Scott D. Priebe	1632			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
THE I - Exter after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on	_·				
2a)⊠ This action is FINAL . 2b)☐ This action		action is non-final.				
3)	Since this application is in condition for allowar					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.			
Dispositi	on of Claims					
4)🖂	Claim(s) <u>8,10,11,13,15,18-27 and 35-55</u> is/are	pending in the application.				
	4a) Of the above claim(s) is/are withdrawn from consideration.					
	Claim(s) is/are allowed.					
	S) Claim(s) <u>8,10,11,13,15,18-27 and 35-55</u> is/are rejected.					
	Claim(s) is/are objected to.	- alastian vasvinamant				
8)[_]	Claim(s) are subject to restriction and/or	election requirement.				
Applicati	on Papers					
9)[The specification is objected to by the Examine	r.				
10)	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
44)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
11)[_]	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority u	ınder 35 U.S.C. § 119					
	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents	s have been received.				
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the prior	·	ed in this National Stage			
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
			<u>.</u>			
Attachmen	t(s)					
	e of References Cited (PTO-892)	4) Interview Summary				
	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal P	ate Patent Application (PTO-152)			
	r No(s)/Mail Date	6) Other:				

Application/Control Number: 08/540,343

Art Unit: 1632

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submissions filed on 9 July 2003 and 19 Sep. 2003 have been entered.

Claim Rejections - 35 USC § 102 & 103

Claims 8, 10, 11, 13, 15, 18-27 remain rejected under 35 U.S.C. 102(e) as being clearly anticipated by Martuza et al., US 5,585,096, filed 7/94 - hereafter Martuza A.

Claims 8, 10, 11, 13, 15, 18-27 remain rejected under 35 U.S.C. 102(e) as being clearly anticipated by Martuza et al., US 5,728,379 (filed 6/1995 and claiming priority to US 5,585,096, filed 7/94) - hereafter Martuza B.

Claims 35-55 are rejected under 35 U.S.C. 103(a) as being unpatentable over McCormick, US 5,846,945 (filed 6/1995, claiming priority to applications filed 2/1994 and 2/1993) in view of a) either Martuza A or Martuza B, or b) Frisch, US 5,776,743 (filed 9/1994); or c) Frisch and either Martuza A or Martuza B.

Application/Control Number: 08/540,343

Art Unit: 1632

Response to Amendment

The declaration filed on 19 Sep. 2003 under 37 CFR 1.131 has been considered but is ineffective to overcome the Martuza references. The evidence submitted is insufficient to establish a reduction to practice of the invention in this country or a NAFTA or WTO member country prior to the effective date of the Martuza references, or to establish diligence from a date prior to the date of reduction to practice of the Martuza references to either a constructive reduction to practice or an actual reduction to practice.

Claims 8, 10, 11, 13, 15, and 18-27 are directed to a method of inhibiting growth of a tumor in vivo, i.e. in a mammal, by administration of an HSV in combination with ionizing radiation. The experimental methods described in the declaration are directed to the effect of ionizing radiation on cultured tumor cells infected with an HSV, and do not involve use of the claimed methods, nor do the claims embrace the experimental methods described. At best, these experiments show evidence relating to the conception of the invention. The declaration provides no evidence of an actual reduction to practice of the invention of claims 8, 10, 11, 13, 15, and 18-27, nor of any diligence up to the constructive reduction to practice upon filing of the instant application. With respect to claims 35-55, the declaration provides no evidence of conception of a method of inhibiting growth of a tumor in vivo, i.e. in a mammal, by administration of an adenovirus in combination with ionizing radiation.

Conclusion

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art

Application/Control Number: 08/540,343

Art Unit: 1632

of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Scott D. Priebe whose telephone number is (571) 272-0733. The examiner can normally be reached on M-F, 8:00-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy J. Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Scott D. Priebe

Primary Examiner

Sitt D. Price

Art Unit 1632